#United States #PTC Therapeutics #stock options #Warren, New Jersey #Nasdaq Listing

PTC Therapeutics Announces New Inducement Grants

On May 1, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) revealed an important development in its employment strategy by approving a series of inducement grants to attract new talent. This initiative comes as part of the company's commitment to creating a competitive compensation package in line with Nasdaq Listing Rule 5635(c)(4).

On April 25, 2025, the company's Compensation Committee granted non-statutory stock options to 12 new employees. These options allow the employees to purchase a total of 7,000 shares of PTC's common stock along with 10,780 restricted stock units (RSUs). Each RSU represents the right to receive one share upon vesting. The move indicates PTC's proactive approach to entice skilled professionals into their fold, particularly within the biopharmaceutical industry, which is increasingly recognized for its innovative medicines supporting rare disorders.

The options granted have an exercise price set at $49.53 per share, which coincides with the closing price of PTC's common stock on the day of the grant. The stock options come with a 10-year term and are designed to vest over a four-year period. Specifically, 25% of the shares will vest on the first anniversary of each employee's hiring date, while the remaining shares will vest at a rate of 6.25% every three months thereafter.

Similarly, the RSUs are set to follow a four-year vesting schedule whereby 25% will vest every annual anniversary of the hiring day. This vesting structure encourages employees to maintain a long-term relationship with the company while also aligning their interests with the overall performance and growth of PTC.

Strategic Growth through Employment Incentives
With these stock options and RSUs, PTC Therapeutics is not just rewarding new hires but also ingraining a performance-oriented culture that rewards contribution towards the company’s success. As a global biopharmaceutical entity, PTC specializes in discovering, developing, and bringing to market differentiated medicines that significantly benefit patients, especially those facing rare disorders. This move is aligned with the company’s ongoing efforts to expand its workforce with highly skilled individuals who will play a vital role in driving PTC's ambitious growth strategy.

Investments in innovative therapies and a strong corporate culture are cornerstones of PTC's strategy as the company strives to enhance its product pipeline and therapeutic offerings—essential elements in an industry that continually needs fresh perspectives and solutions. By positioning itself as an employer of choice, PTC Therapeutics aims to secure the human capital necessary for its planned growth trajectory in the increasingly competitive biopharmaceutical market.

About PTC Therapeutics
PTC Therapeutics is a globally recognized biopharmaceutical company dedicated to discovering and developing treatments that significantly improve the lives of those with rare diseases. The company prides itself on having a transformative pipeline of medicines creating breakthrough solutions in healthcare.

For more information about PTC Therapeutics and their latest advancements, visit www.ptcbio.com and follow them on social media platforms such as Facebook, X, and LinkedIn.